2013: Prize of Scientific Excellence
Our team is interested in rare cancers in which we investigate fundamental mechanisms linking genetic disorders to energy metabolism, angiogenesis, epigenetic reprogramming and carcinogenesis. It is composed of biologists and clinicians involved in the management of patients at different levels (genetics, urology, pathology, hypertension, oncology and nuclear medicine). We address fundamental questions through the study of oncogenic pathways associated with mitochondrial dysfunction and develop translational research projects through human genetics, biomarker identification and validation, as well as proof-of-concept studies for new therapeutics.